The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.
 
Helen J. Ross
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Genentech (Inst); Halozyme (Inst); Ignyta (Inst); Merck (Inst); Tesaro (Inst)
 
David E. Kozono
Consulting or Advisory Role - Vertex
 
James John Urbanic
No Relationships to Disclose
 
Terence Marques Williams
No Relationships to Disclose
 
Carter Dufrane
No Relationships to Disclose
 
Ilze Bara
Employment - Genentech
 
Mayank Gandhi
Employment - Genentech
 
Katja Schulze
Employment - Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Jane Michelle Brockman
Employment - Genentech
 
Xiaofei F. Wang
No Relationships to Disclose
 
Everett E. Vokes
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Bayer; Biolumina; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Leidos Biomedical Research; Lilly; Merck; Novartis; Regeneron; Takeda; VentiRx
 
Tom Stinchcombe
Consulting or Advisory Role - AstraZeneca; Novartis; Regeneron; Takeda
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Merck (Inst); Takeda (Inst)